Larimar Therapeutics, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
42Larimar rapeutics's Business Model
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
About Larimar rapeutics
Website: https://www.larimartx.com
CEO (Chief Executive Officer): Dr. Carole S. Ben-Maimon M.D.
IPO date: 2014-06-19
Contact
Country: US
Address: Three Bala Plaza East
City: Bala Cynwyd
State: PA
Phone: 844 511 9056
Zip Code: 19004
Other
CIK: 0001374690
ISIN: US5171251003
CUSIP: 517125100
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
